Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q2 EPS of ($0.86), $0.09 better than the analyst estimate of ($0.95).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.